EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 40 / Numéro 11 (Novembre 2024) Med Sci (Paris), 40 11 (2024) 848-857 Références
Open Access
Numéro
Med Sci (Paris)
Volume 40, Numéro 11, Novembre 2024
Page(s) 848 - 857
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2024151
Publié en ligne 10 décembre 2024
  1. Singh V, Khan N, Jayandharan GR. Vector engineering, strategies and targets in cancer gene therapy. Cancer Gene Ther 2022 ; 29 : 402–17. [CrossRef] [PubMed] [Google Scholar]
  2. Tanyi JL, Bobisse S, Ophir E, et al. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med 2018 ; 10 : eaao5931. [CrossRef] [PubMed] [Google Scholar]
  3. June CH, O’Connor RS, Kawalekar OU, et al. CAR T cell immunotherapy for human cancer. Science 2018 ; 359 : 1361–5. [CrossRef] [PubMed] [Google Scholar]
  4. Paulson KG, Voillet V, McAfee MS, et al. Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nat Commun 2018 ; 9 : 3868. [Google Scholar]
  5. Rosenberg SA, Eberlein TJ, Grimm EA, et al. Development of long-term cell lines and lymphoid clones reactive against murine and human tumors: a new approach to the adoptive immunotherapy of cancer. Surgery 1982 ; 92 : 328–36. [PubMed] [Google Scholar]
  6. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986 ; 233 : 1318–21. [CrossRef] [PubMed] [Google Scholar]
  7. Sadelain M. Methods for retrovirus-mediated gene transfer into primary T-lymphocytes. Methods Mol. Med. 1997 ; 7 : 241–8. [Google Scholar]
  8. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A 1989 ; 86 : 10024–8. [CrossRef] [PubMed] [Google Scholar]
  9. Eshhar Z, Waks T, Gross G, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 1993 ; 90 : 720–4. [CrossRef] [PubMed] [Google Scholar]
  10. Sadelain M. CD19 CAR T Cells. Cell 2017 ; 171 : 1471. [CrossRef] [PubMed] [Google Scholar]
  11. Park JR, Digiusto DL, Slovak M, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007 ; 15 : 825–33. [Google Scholar]
  12. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006 ; 12 : 6106–15. [CrossRef] [PubMed] [Google Scholar]
  13. Marofi F, Motavalli R, Safonov VA, et al. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res Ther. 2021 ; 12 : 81. [CrossRef] [Google Scholar]
  14. Stegen SJC van der, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov 2015 ; 14 : 499–509. [CrossRef] [PubMed] [Google Scholar]
  15. Till BG, Jensen MC, Wang J, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012 ; 119 : 3940–50. [CrossRef] [PubMed] [Google Scholar]
  16. Ramos CA, Rouce R, Robertson CS, et al. In Vivo Fate and Activity of Second-versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin’s Lymphomas. Mol Ther 2018 ; 26 : 2727–37. [Google Scholar]
  17. Schubert M-L, Schmitt A, Hückelhoven-Krauss A, et al. Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial. J Hematol Oncol 2023 ; 16 : 79. [CrossRef] [PubMed] [Google Scholar]
  18. Enblad G, Karlsson H, Gammelgård G, et al. A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia. Clin Cancer Res 2018 ; 24 : 6185–94. [CrossRef] [PubMed] [Google Scholar]
  19. Tomasik J, Jasiński M, Basak GW. Next generations of CAR-T cells - new therapeutic opportunities in hematology? Front Immunol 2022 ; 13 : 1034707. [CrossRef] [PubMed] [Google Scholar]
  20. Glienke W, Dragon AC, Zimmermann K, et al. GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18. Front Immunol 2022 ; 13 : 839783. [CrossRef] [PubMed] [Google Scholar]
  21. Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther 2015 ; 15 : 1145–54. [CrossRef] [PubMed] [Google Scholar]
  22. Tokarew N, Ogonek J, Endres S, et al. Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer 2019 ; 120 : 26–37. [CrossRef] [PubMed] [Google Scholar]
  23. Uscanga-Palomeque AC, Chávez-Escamilla AK, Alvizo-Báez CA, et al. CAR-T Cell Therapy: From the Shop to Cancer Therapy. Int J Mol Sci 2023 ; 24 : 15688. [CrossRef] [PubMed] [Google Scholar]
  24. Zhang P, Zhang G, Wan X. Challenges and new technologies in adoptive cell therapy. J Hematol Oncol 2023 ; 16 : 97. [CrossRef] [PubMed] [Google Scholar]
  25. Zhao J, Lin Q, Song Y, et al. Universal CARs, universal T cells, and universal CAR T cells. J Hematol Oncol 2018 ; 11 : 132. [CrossRef] [PubMed] [Google Scholar]
  26. Lonez C, Breman E. Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met? Cells 2024 ; 13 : 146. [CrossRef] [PubMed] [Google Scholar]
  27. Eyquem J, Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 2017 ; 543 : 113–7. [NASA ADS] [CrossRef] [PubMed] [Google Scholar]
  28. Jayaraman J, Mellody MP, Hou AJ, et al. CAR-T design: Elements and their synergistic function. EBioMedicine 2020 ; 58 : 102931. [CrossRef] [PubMed] [Google Scholar]
  29. Lamers CHJ, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006 ; 24 : e20–2. [CrossRef] [PubMed] [Google Scholar]
  30. Lamers CH, Sleijfer S, Steenbergen S van, et al. Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity. Mol Ther 2013 ; 21 : 904. [Google Scholar]
  31. Daei Sorkhabi A, Mohamed Khosroshahi L, Sarkesh A, et al. The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies. Front Immunol. 2023 ; 14 : 1113882. [CrossRef] [Google Scholar]
  32. Mackensen A, Müller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 2022 ; 28 : 2124–32. [Google Scholar]
  33. Müller F, Taubmann J, Bucci L, et al. CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up. N Engl J Med 2024 ; 390 : 687–700. [CrossRef] [PubMed] [Google Scholar]
  34. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 2016 ; 127 : 3321–30. [CrossRef] [PubMed] [Google Scholar]
  35. Kadauke S, Myers RM, Li Y, et al. Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial. J Clin Oncol 2021 ; 39 : 920–30. [CrossRef] [PubMed] [Google Scholar]
  36. Gust J, Hay KA, Hanafi L-A, et al. Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discov 2017 ; 7 : 1404–19. [CrossRef] [PubMed] [Google Scholar]
  37. Hu Y, Sun J, Wu Z, et al. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. J Hematol Oncol 2016 ; 9 : 70. [CrossRef] [PubMed] [Google Scholar]
  38. Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther J 2010 ; 18 : 843–51. [CrossRef] [Google Scholar]
  39. Orlando EJ, Han X, Tribouley C, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med 2018 ; 24 : 1504–6. [CrossRef] [PubMed] [Google Scholar]
  40. Kankeu Fonkoua LA, Sirpilla O, Sakemura R, et al. CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities. Mol Ther - Oncolytics 2022 ; 25 : 69–77. [CrossRef] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.